168 related articles for article (PubMed ID: 31500928)
21. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
22. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
24. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
25. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.
Xiao S; Zhang M; Liu C; Wang D
Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546
[TBL] [Abstract][Full Text] [Related]
26. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
27. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
29. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
30. miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression.
Choi N; Park J; Lee JS; Yoe J; Park GY; Kim E; Jeon H; Cho YM; Roh TY; Lee Y
Oncotarget; 2015 Sep; 6(27):23533-47. PubMed ID: 26124181
[TBL] [Abstract][Full Text] [Related]
31. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
32. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
33. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
34. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
35. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
36. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
37. Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer.
Shao X; Mei W; Weng W; Qin J; Zhou J; Liu J; Cheng J
Int J Clin Exp Pathol; 2013; 6(6):1095-102. PubMed ID: 23696927
[TBL] [Abstract][Full Text] [Related]
38. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
[TBL] [Abstract][Full Text] [Related]
39. Oleuropein reduces cisplatin resistance in ovarian cancer by targeting apoptotic pathway regulators.
Hashemi Sheikhshabani S; Amini-Farsani Z; Rahmati S; Jazaeri A; Mohammadi-Samani M; Asgharzade S
Life Sci; 2021 Aug; 278():119525. PubMed ID: 33894272
[TBL] [Abstract][Full Text] [Related]
40. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]